CPS
  • Home

Breast Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head & Neck Cancer, Urothelial Carcinoma​​

Coming soon: PD-L1 IHC 22C3 pharmDx Interpretation Training Program for Combined Positive Score (CPS) Indications​

PD-L1 testing provides a direct assessment of PD-L1 expression, which is a biomarker for response to anti-PD-1 therapy in certain indications. Get educated on how to evaluate and score PD‑L1 expression using PD‑L1 IHC 22C3 pharmDx. This PD-L1 IHC 22C3 pharmDx Interpretation Training Program provides education that may help you accurately evaluate and score PD‑L1 expression in patients using the Combined Positive Score (CPS). ​ NB! This training program will be available on the portal soon. If you need access to an existing PD-L1 IHC 22C3 pharmDx Interpretation Training Program, please reach out via the “Help” page.

    clockimg 2h
  • Interactive
  • Foundational
 saveimgSave unsaveimgUnsave

The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:​

  • Understand the core principles of PD-L1 pathology​
  • Learn the process for evaluating stained images for PD-L1 expression​
  • Recognize confounding considerations that affect PD-L1 interpretation​
  • Score images for PD-L1 expression across a variety of patient samples using the Combined Positive Score (CPS)​

 

Review the Intended Use for PD-L1 IHC 22C3 pharmDx.

Related Training

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.​ D0113784_1.00